Last Updated : May 15, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort ascending | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Orgovyx | relugolix | Advanced prostate cancer | Active | |||
| Elrexfio | elranatamab | Relapsed or refractory multiple myeloma | Active | |||
| Opdivo | nivolumab | Stage IIB or IIC melanoma, adjuvant | Active | |||
| TBC | lebrikizumab | atopic dermatitis | Active | |||
| Prevymis | letermovir | Cytomegalovirus infection (CMV), prophylaxis | Withdrawn | |||
| TBC | ruxolitinib | atopic dermatitis | Suspended | |||
| Bimzelx | bimekizumab | Ankylosing spondylitis | Active | |||
| Awiqli | insulin icodec | Diabetes mellitus, type 2 | Active | |||
| Jemperli | dostarlimab | Endometrial cancer | Active | |||
| Isturisa | osilodrostat | Endogenous Cushing’s syndrome | Suspended |
Last Updated : May 15, 2024